Qiagen

DeepUll raises €13M Series B financing to progress early sepsis recognition platform

Retrieved on: 
Thursday, October 20, 2022
Sepsis, Vista Equity Partners, ICU, QIAGEN, Intelligence, Patient, CDTI, Blood culture, Mortality, Qiagen, Prognosis, UI, ER, Axis, Pharmaceutical industry, Medical device, Science

DeepUll was founded in 2020 to create rapid, affordable and accessible diagnostic solutions with a specific focus on culture-free diagnostics to enable sepsis recognition in pre-symptomatic patients.

Key Points: 
  • DeepUll was founded in 2020 to create rapid, affordable and accessible diagnostic solutions with a specific focus on culture-free diagnostics to enable sepsis recognition in pre-symptomatic patients.
  • The funds will be used to progress the development of DeepUlls first-in-class sepsis recognition platform towards the market.
  • Early sepsis recognition is vital in improving patient prognosis and reducing mortality.
  • Our mission is to change this and this financing will allow us to ramp up our efforts to bring our first-in-class sepsis recognition platform to market.

Predicting the Next Emerging Disease Requiring In Vitro Diagnostics (IVDs)

Retrieved on: 
Wednesday, October 12, 2022
Chagas, Kalorama, Mosquito control, OraSure Technologies, Method, Infection, Ortho Clinical Diagnostics, Tuberculosis, BGI, Bird, BD (company), Roche, Rift Valley fever, CCHF, Dengue fever, SD, InBios, Spider, World, Qiagen, Marketing, IVD, Siemens Healthineers, World Health Organization, Nipa, Yellow fever, Adult, Lassa fever, Thermo Fisher Scientific, Cepheid variable, Bass, TB, Abbott, Pharmaceutical industry, Vaccine, Chikungunya, West Nile virus, Malaria, Turtle, Bruker, Goldfish, Ross River virus

ARLINGTON, Va., Oct. 12, 2022 /PRNewswire-PRWeb/ -- Kalorama estimates a $3.7 billion market for emerging diseases. This market is expected to grow to $4.9 billion in 2026. This is based on its recent report "Emerging Infectious Disease Market Trends, 2022."

Key Points: 
  • ARLINGTON, Va., Oct.12, 2022 /PRNewswire-PRWeb/ -- Kalorama estimates a $3.7 billion market for emerging diseases.
  • This is based on its recent report " Emerging Infectious Disease Market Trends, 2022 ."
  • For many mosquito-borne illnesses, there is no vaccine and little in the way of treatment as the infections are viral.
  • Non mosquito-spread diseases of concern include: Tuberculosis, Chagas, Lyme Disease Marburg virus, Rift Valley Fever, Ebola, Ross River Virus, CCHF, Nipah and Lassa Fever.

Nanomix Appoints Industry Veteran Tadd S. Lazarus, M.D., to the Board of Directors

Retrieved on: 
Wednesday, August 31, 2022
Lazarus, Health care, VP, Security (finance), Private practice, CEO, Analyser, OTCQB, CRP, SAN, Elab, Time, Ross University School of Medicine, Decision-making, C-reactive protein, North American Medical Management, Board, Medicine, Point-of-care testing, Bureau of Oceans and International Environmental and Scientific Affairs, Qiagen, Forward-looking statement, Medical degree, Medication, U.S. Securities and Exchange Commission, Organization, Procalcitonin, Point of care, GLOBE, PCT, Leadership, Company, MHRA, Marlboro College, Public policy, Roche Diagnostics, Sepsis, Biochemistry, Diabetes, Director, POC, CE, Industry, Physiology, Growth, LAC, Health, Management, Medical device, Science, MD

We are extremely pleased to welcome Tadd S. Lazarus, M.D., to the board and leadership of the Company, said Dr. Thomas Schlumpberger, CEO of Nanomix.

Key Points: 
  • We are extremely pleased to welcome Tadd S. Lazarus, M.D., to the board and leadership of the Company, said Dr. Thomas Schlumpberger, CEO of Nanomix.
  • Dr. Lazarus brings an important medical and industry perspective to the Nanomix Board, said Garrett Gruener, Chairman of the Nanomix Board of Directors.
  • Tadds input and counsel will be very valuable as we accelerate our commercial efforts and broaden our product portfolio.
  • I am thrilled about working with the Nanomix team to fully develop the exciting eLab mobile diagnostics testing platform.

Sharon Robins Joins Precipio’s Products Division as Senior Director of Laboratory & Hospital Sales

Retrieved on: 
Wednesday, August 24, 2022
Patient, COVID-19, Spruce Production Division, Securities Exchange Act of 1934, Securities Act of 1933, Quest Diagnostics, Gene, Government, Laboratory, NASDAQ, Coronavirus, Thermo, Thermo Fisher Scientific, U.S. Securities and Exchange Commission, GLOBE, Leadership, Company, Efficiency, Exon, Annual report, Growth, Life Technologies, Qiagen, HAVEN

NEW HAVEN, Conn., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , welcomes Sharon Robins as the Companys Senior Director of Laboratory & Hospital Sales for the Products Division.

Key Points: 
  • NEW HAVEN, Conn., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , welcomes Sharon Robins as the Companys Senior Director of Laboratory & Hospital Sales for the Products Division.
  • Coming from Qiagen, a market leader in the diagnostic reagents field, Ms. Robins brings with her a strong background in multiple leadership positions in diagnostic product sales.
  • Sharon has a strong background in diagnostics distribution, previously holding senior sales positions at Quest Diagnostics, ThermoFisher, and Life Technologies.
  • Her experience in diagnostic reagents sales & distribution is exactly what we need to ensure the growth we are anticipating through the recent distribution agreements the company has signed, said Keith Meadors, Precipios SVP Products Division.

Foresite Labs Appoints Uplaksh Kumar, Former GRAIL and Verily Operations Lead, to Chief Operating Officer

Retrieved on: 
Wednesday, August 17, 2022
Science, Other Science, Biotechnology, Research, Health, Data Management, Health Technology, Technology, CEO, SVP, B cell, Investment, Regenerative medicine, History of the University of Maryland, College Park, Foresite Capital, University, Research, Data science, BD, GRAIL, COO, CSO, CTO, Life Technologies, Science, Verily, Pharmacy, Labs, IPO, Disease, Management, Fine chemical, Pharmaceutical industry, Qiagen, Science Gallery

Foresite Labs today announced the appointment of Uplaksh Kumar as its chief operating officer (COO).

Key Points: 
  • Foresite Labs today announced the appointment of Uplaksh Kumar as its chief operating officer (COO).
  • Prior to joining Foresite Labs, Uplaksh Kumar was the SVP of strategic operations and scale at GRAIL , where he launched the Galleri test, a multi-cancer early detection test.
  • Kumar will focus on leading the operations functions for Foresite Labs and efficiently scaling Foresite Labs incubated companies.
  • It also comes after Foresite Capital's latest announcement of $173 million raised to invest in Foresite Labs funded companies.

Blood Collection Market size worth $ 13.2 Billion, Globally, by 2030 at 5.1% CAGR: Verified Market Research®

Retrieved on: 
Wednesday, August 17, 2022
Lists of diseases, Injury, Death, Qiagen, Growth, USD, Blood, GE Healthcare, Trauma, Patient, Company, Acquisition, BD, Medtronic, GE Ventures, Conditional sentence, Partnership, Accident, CAGR, Geography, Research, Dickinson, BD (company), Hospital, Pharmacy, Health, Market research, Becton, Medical device, Pharmaceutical industry, Method

JERSEY CITY, N.J., Aug. 17, 2022 /PRNewswire/ -- Verified Market Research recently published a report, "Blood Collection Market" By Product (Blood Collection Tubes, Blood Bags), By Method (Manual Blood Collection, Automated Blood Collection), By End User (Hospitals And Pathology Laboratories, Blood Banks), and By Geography. According to Verified Market Research, the Blood Collection Market size was valued at USD 8.9 Billion in 2021 and is projected to reach USD 13.2 Billion by 2030, growing at a CAGR of 5.1% from 2022 to 2030. 

Key Points: 
  • JERSEY CITY, N.J., Aug. 17, 2022 /PRNewswire/ --Verified Market Research recently published a report, " Blood Collection Market " By Product (Blood Collection Tubes, Blood Bags), By Method (Manual Blood Collection, Automated Blood Collection), By End User (Hospitals And Pathology Laboratories, Blood Banks), and By Geography.
  • According to Verified Market Research, the Blood Collection Market size was valued at USD 8.9 Billion in 2021 and is projected to reach USD 13.2 Billion by 2030, growing at a CAGR of 5.1% from 2022 to 2030.
  • The increasing number of chronic diseases globally, are driving the expansion of the worldwide Blood Collection Market.
  • Verified Market Research has segmented the Global Blood Collection Market On the basis of Product, Method, End User, and Geography.

Global Clinical Laboratory Services Markets, 2022-2028: Focus on Clinical Chemistry, Medical Microbiology & Cytology, Human & Tumor Genetics, Immunology Testing, & Genetic Testing - ResearchAndMarkets.com

Retrieved on: 
Friday, July 15, 2022
Health, Medical Supplies, Medical Devices, Conditional sentence, LabCorp, Laboratory, Lists of countries and territories, Siemens Healthineers, Genetic testing, Immunology, Qiagen, Charles River Laboratories, Diabetes, ARUP Laboratories, COVID-19, Growth, Prevalence, Clinical chemistry, Abbott Laboratories, Government, Pharmaceutical industry

Further, the significant launch of new kits is expected to contribute to the market growth.

Key Points: 
  • Further, the significant launch of new kits is expected to contribute to the market growth.
  • The rise in the geriatric population and initiatives from the government for in-vitro diagnostics will further contribute to the growth of the Clinical Laboratory Services market.
  • The clinical laboratory services market is segmented based on type and service provider.
  • By type, the market is segmented into clinical chemistry, medical microbiology & cytology, human & tumor genetics, Immunology testing, genetic testing, and others.

Global microRNA Industry Report 2022-2027 Featuring Profiles of Thermo Fisher Scientific, Horizon Discovery, QIAGEN, BioGenex, and GeneCopoeia Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 13, 2022
Pharmaceutical, Health, COVID-19, Aurora, Prevalence, MicroRNA, Safety, Biotechnology, National Center for Biotechnology Information, Umi, Diabetes, National Center for Medical Intelligence, Severe acute respiratory syndrome coronavirus 2, Risk, PerkinElmer, American Cancer Society, Patient, Degenerative disease, Mirna, COVID-19, Megasphaera, Qiagen, Rare disease, Illumina, Inc., Disorder, Toxicity, RNA, Atherosclerosis, Technology, Research, Genome, Adoption, Cancer, Coronavirus, USD, Conditional sentence, Pharmaceutical industry, Growth

The "microRNA Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "microRNA Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The expression of these miRNAs, on the other hand, is useful in detecting SARS-CoV-2 infection.
  • With the increase in research and development activity, many regional players are expected to be part of the microRNA market over the forecast period.
  • Some of the major players in the market are Thermo Fisher Scientific, Inc., Qiagen N.V., Illumina, Inc., PerkinElmer, Inc., and Takara Bio, Inc.

Global Genotyping Market Analysis Report 2022: A $46.5 Billion Market by 2030 - Focus on PCR, Capillary Electrophoresis, Microarrays, Sequencing, & Mass Spectrometry - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022
Health, Genetics, CAGR, Cobas, Therapy, Drug development, COVID-19, Medical Research Future Fund, Genomics, SNP, GT, Vaccine, Government, Bias, Thermo Fisher Scientific, Genotyping, Pharmacogenomics, Qiagen, Cancer, Research, Growth, USD, Mass spectrometry, Aquaculture, Roche, Alzheimer's disease, Partnership, Local government in Australia, Parkinson's disease, Lists of diseases, Patient, Application, Diagnosis, Genetic testing, Awareness, Center, COVID, PCR, Organization, Prevalence, Cervical cancer, NIH, Pharmaceutical industry, Animal, Fine chemical, Illumina, Color, Technology

Governments in multiple countries are taking various initiatives to provide support and funding to research organizations for personalized medicine, and genotyping research is anticipated to drive the market.

Key Points: 
  • Governments in multiple countries are taking various initiatives to provide support and funding to research organizations for personalized medicine, and genotyping research is anticipated to drive the market.
  • For instance, in August 2019, NIH funded USD 4.6 million initial grants to Color, a health technology company, for precision medicine initiatives and development.
  • Similarly, in 2018, the Government of Australia launched the Australian Genomics Health Futures Mission initiative.
  • North America accounted for the largest market share in 2021, owing to proactive government measures, high disease prevalence, technological advancements, and advanced healthcare infrastructure.

Lung Cancer Genomic Testing Markets, 2031 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 21, 2022
Health, Oncology, EGFR, CAGR, ROS, Cobas, FDA, Drug development, COVID-19, ALK, Polymerase chain reaction, FISH, LabCorp, Qiagen, IVD, Precision medicine, Efficiency, LDT, MET, Polymerase, Adoption, Research, Hospital, BIS, Growth, Takeda, Real-time polymerase chain reaction, Cdx, DNA sequencing, NGS, Investment, Roche, Quest Diagnostics, Thermo Fisher Scientific, Amgen, Partnership, Fluorescence in situ hybridization, Region, Lung cancer, Patient, KRAS, In situ hybridization, Diagnosis, Awareness, PCR, Organization, Large-cell lung carcinoma, Antibiotics, Medical imaging, Technology, Fluorescence, NSCLC

The growth in the global lung cancer genomic testing market is expected to be driven by increasing awareness and adoption of the lung cancer genomic testing market, recent launches of novel lung cancer genomic testing, and the expanding research in the field of lung cancer with an emphasis on pharmacogenomics and development of companion diagnostics.

Key Points: 
  • The growth in the global lung cancer genomic testing market is expected to be driven by increasing awareness and adoption of the lung cancer genomic testing market, recent launches of novel lung cancer genomic testing, and the expanding research in the field of lung cancer with an emphasis on pharmacogenomics and development of companion diagnostics.
  • Various companies are increasing investments in research and development to facilitate the development of lung cancer genomic testing, which is expected to further increase the adoption of lung cancer genomic tests.
  • Increasing recommendations by the international oncology societies for the use of genomic testing for lung cancer diagnosis provides major opportunities in the global lung cancer genomic testing market.
  • Since the lung cancer genomic testing is categorized under the elective procedure, the impact of the COVID-19 pandemic on the lung cancer genomic testing was negative.